Send us a text

Back in March 2023, Jeff McIntyre (GLI) introduced a draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. The Surfers dedicated an episode to expand on the contents, its shortcomings and potential implications with special guests Veronica Miller (Liver Forum) and Hannah Mamuszka (Alva10). This week, SurfingNASHrevisits the topic after a public comments session took place last week. In doing so, patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions.

This final conversation focuses on the most important thing each panelist would like ICER to learn before another NASH drug analysis. In our first conversation with Jeff McIntyre, he said that it while it was appreciated that patients have a voice, it's not the same as having a vote. The patient advocate comments in this conversation make it clear exactly how wide the gap between the two is right now. Fortunately, as Veronica miller noted during that preceding episode, ICER reporting has no impact on FDA decisions. However, as we discuss during this conversation, it might have an impact on payers.

If you enjoy the episode, have questions or interest around patient advocacy and Fatty Liver disease, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected].

Stay Safe and Surf On!